Back to Search
Start Over
A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.
- Source :
-
The British journal of radiology [Br J Radiol] 2017 Mar; Vol. 90 (1071), pp. 20160732. Date of Electronic Publication: 2017 Feb 17. - Publication Year :
- 2017
-
Abstract
- Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.
Details
- Language :
- English
- ISSN :
- 1748-880X
- Volume :
- 90
- Issue :
- 1071
- Database :
- MEDLINE
- Journal :
- The British journal of radiology
- Publication Type :
- Academic Journal
- Accession number :
- 27885858
- Full Text :
- https://doi.org/10.1259/bjr.20160732